実験的マウス結核症に対するbenzoxazinorifamycin : KRM-1648のin vivo治療効果 : (1) 経気道感染モデルと尾静脈感染モデルを用いた短期治療効果の検討 THERAPEUTIC EFFICACY OF BENZOXAZINORIFAMYCIN KRM-1648 : AGAINST EXPERIMENTAL MURINE TUBERCULOSIS : (1)A Study on the Efficacy of Short Course Treatment with the Intratracheal and Intravenous Infection Models

この論文にアクセスする

この論文をさがす

著者

    • 土井 教生 DOI Norio
    • 結核予防会結核研究所基礎研究部 the Department of Basic Research, Research Institute of Tuberculosis, Japan Anti-Tuberculosis Association

抄録

Objectives: This study aims to compare <I>in vivo</I> activity of benzoxazinorifamycin KRM-1648 (KRM) with those of rifampicin (RFP) and rifabutin (RBT) against experimental murine tuberculosis.<BR>Study design: Mice were infected with <I>Mycobacterium tuberculosis</I> or <I>M. bovis</I> by the intratracheal (IT) or intravenous (IV) routes, and treated for 10 days with various doses of each drug starting from the 8th or 11th day after the TB-infection.<BR>Results: (A) A rapid test for <I>in vivo</I> evaluation of three rifamycins was conducted by examining the survival days of treated mice infected with 10<SUP>6</SUP> cfu of <I>M. bovis</I> Ravenel. Mice treated with KRM exhibited 2.1-3.7 times longer survival times, in comparison with those treated with RFP or RBT. (B) In the IT-model of <I>M. bovis</I> Ravenel infection, three rifamycin derivatives gave "distinctive dose-response curves" in the correlation of dose sizes with the mean survival times or "log<SUB>10</SUB> CFU/lungs reductions". (C) In <I>M. tuberculosis</I> Kurono infection models, the ranking of the anti-TB activity of the three rifamycins in each organ was as follows: IT-and IV-lungs: KRM>RFP=RBT, IV-spleen: KRM≈≈RBT>RFP, IV-liver: KRM≈RBT>RFP. (D) Based on the results of"log<SUB>10</SUB>CFU reductions"in different organs in <I>M. tuberculosis</I> Kurono infection models, "characteristic in vivo activity patterns of each rifamycin" were obtained. (E) The therapeutic efficacy of KRM in lungs was greater than in spleen and liver with any dose. In contrast, RBT exhibited more remarkable <I>in vivo</I> activity in the spleen and liver than in lungs.<BR>Conclusion: The prominent <I>in vivo</I> activity of KRM may allow small dose for effective therapy;1/3 dose or less in comparison with those of RFP or RBT, or intermittent therapy of tuberculosis.

収録刊行物

  • 結核

    結核 73(2), 53-64, 1998-02-15

    JAPANESE SOCIETY FOR TUBERCULOSIS

参考文献:  43件中 1-43件 を表示

被引用文献:  5件中 1-5件 を表示

各種コード

  • NII論文ID(NAID)
    10008113284
  • NII書誌ID(NCID)
    AN00073442
  • 本文言語コード
    JPN
  • 資料種別
    ART
  • ISSN
    00229776
  • データ提供元
    CJP書誌  CJP引用  J-STAGE 
ページトップへ